Alentemol

Alentemol' (International Nonproprietary Name: INN), known during its development under the code name U-66444B, is a pharmacological compound classified as a selective dopamine autoreceptor agonist. It has been described in the literature as an antipsychotic due to its potential therapeutic effects on psychiatric disorders through modulation of dopamine pathways. Despite the promise shown in early research phases, Alentemol was never introduced to the market for clinical use.

Pronunciation

Ah-len-teh-mol

Etymology

The etymology of "Alentemol" is not explicitly documented. However, the naming convention suggests a typical pharmaceutical blend, potentially combining elements related to its action or chemical structure with a suffix common to drugs ("-ol"), indicating its role as an active compound. The developmental code name "U-66444B" follows the pattern of alphanumeric identifiers assigned by research institutions or pharmaceutical companies during the drug discovery and development process.

Pharmacodynamics

As a selective dopamine autoreceptor agonist, Alentemol is designed to target autoreceptors on dopaminergic neurons. These receptors, when activated, play a key role in regulating the synthesis and release of dopamine, a neurotransmitter critically involved in reward, motivation, and many aspects of psychiatric pathology. By modulating the activity of these autoreceptors, Alentemol aimed to offer a novel approach to managing conditions characterized by dopamine dysregulation, such as schizophrenia and other psychotic disorders.

Clinical Development and Discontinuation

The development of Alentemol included preclinical and possibly early clinical studies to assess its efficacy and safety profile as an antipsychotic agent. Despite initial research suggesting its potential utility in treating psychiatric disorders, the development of Alentemol was halted before it could be marketed. The reasons for discontinuation could range from insufficient efficacy in clinical trials, challenges in managing side effects, or strategic decisions based on the competitive landscape of antipsychotic medications.

Implications for Antipsychotic Drug Development

The case of Alentemol highlights the challenges inherent in developing new antipsychotic medications, particularly those targeting the complex dopamine system. It underscores the importance of continued innovation and exploration within the field of neuropsychopharmacology to discover more effective and safer treatments for psychiatric conditions.

Related Terms

• Dopamine Autoreceptor
• Antipsychotic
• Schizophrenia
• Psychiatric Disorder
• Neurotransmitter

See Also

• Dopamine
• Psychopharmacology
• Drug Development Process
• Neuropsychiatric Medication
• Selective Agonist

External links

• Medical encyclopedia article on Alentemol
• Wikipedia's article - Alentemol

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski